[go: up one dir, main page]

WO2010150233A3 - Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof - Google Patents

Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof Download PDF

Info

Publication number
WO2010150233A3
WO2010150233A3 PCT/IB2010/052917 IB2010052917W WO2010150233A3 WO 2010150233 A3 WO2010150233 A3 WO 2010150233A3 IB 2010052917 W IB2010052917 W IB 2010052917W WO 2010150233 A3 WO2010150233 A3 WO 2010150233A3
Authority
WO
WIPO (PCT)
Prior art keywords
hla
alpha3
multimeric polypeptides
multimers
pharmaceutical uses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2010/052917
Other languages
French (fr)
Other versions
WO2010150233A2 (en
Inventor
Joël LE MAOULT
Edgardo Delfino Carosella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to JP2012516958A priority Critical patent/JP5736368B2/en
Priority to ES10732451.9T priority patent/ES2515241T3/en
Priority to CA2764860A priority patent/CA2764860C/en
Priority to EP10732451.9A priority patent/EP2445934B1/en
Priority to US13/379,525 priority patent/US20120178703A1/en
Publication of WO2010150233A2 publication Critical patent/WO2010150233A2/en
Publication of WO2010150233A3 publication Critical patent/WO2010150233A3/en
Anticipated expiration legal-status Critical
Priority to US15/868,119 priority patent/US11401318B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Multimeric polypeptides and pharmaceutical uses thereof; multimers comprising alpha3 peptides of an HLA-G antigen and methods of producing such multimers, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection. Said multimers comprise at least two monomers, each of said monomers being selected in the group consisting of a peptide Pl of formula X1 -X2, wherein X1 represents a peptidic linker including a cysteine amino acid and X2 represents an alpha3 domain of HLA-G.
PCT/IB2010/052917 2009-06-25 2010-06-25 Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof Ceased WO2010150233A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2012516958A JP5736368B2 (en) 2009-06-25 2010-06-25 HLA-G multimeric polypeptide comprising at least two α3 domains and use thereof as a medicament
ES10732451.9T ES2515241T3 (en) 2009-06-25 2010-06-25 HLA-G multimer polypeptides that include at least two alpha3 domains and pharmaceutical uses thereof
CA2764860A CA2764860C (en) 2009-06-25 2010-06-25 Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
EP10732451.9A EP2445934B1 (en) 2009-06-25 2010-06-25 Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
US13/379,525 US20120178703A1 (en) 2009-06-25 2010-06-25 Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
US15/868,119 US11401318B2 (en) 2009-06-25 2018-01-11 Multimeric polypeptides of HLA-G including at least two alpha3 domains and pharmaceutical uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IBPCT/IB2009/006491 2009-06-25
IB2009006491 2009-06-25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/379,525 A-371-Of-International US20120178703A1 (en) 2009-06-25 2010-06-25 Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
US15/868,119 Division US11401318B2 (en) 2009-06-25 2018-01-11 Multimeric polypeptides of HLA-G including at least two alpha3 domains and pharmaceutical uses thereof

Publications (2)

Publication Number Publication Date
WO2010150233A2 WO2010150233A2 (en) 2010-12-29
WO2010150233A3 true WO2010150233A3 (en) 2011-05-12

Family

ID=42710707

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2010/052917 Ceased WO2010150233A2 (en) 2009-06-25 2010-06-25 Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
PCT/IB2010/052920 Ceased WO2010150235A1 (en) 2009-06-25 2010-06-25 Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/052920 Ceased WO2010150235A1 (en) 2009-06-25 2010-06-25 Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof

Country Status (6)

Country Link
US (3) US9359424B2 (en)
EP (2) EP2445935B1 (en)
JP (2) JP5802661B2 (en)
CA (2) CA2764649C (en)
ES (2) ES2546509T3 (en)
WO (2) WO2010150233A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359424B2 (en) 2009-06-25 2016-06-07 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of HLA-G including alpha1-alpha3 monomers and pharmaceutical uses thereof
EP2730588A1 (en) * 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
BR112015013557B1 (en) 2012-12-11 2021-12-14 Albert Einstein College Of Medicine SYSTEM, METHOD, METHOD FOR DETERMINING THE EFFECT OF A PREDETERMINED AMINO ACID RESIDUE OF A FIRST PROTEIN ON BINDING OF THE FIRST PROTEIN TO A SECOND PROTEIN AND MUTANT PD-L1 POLYPEPTIDE
JP6416480B2 (en) * 2014-01-29 2018-10-31 国立大学法人北海道大学 Preventive or therapeutic agent for rheumatoid arthritis or related diseases
SG10202009095VA (en) * 2014-11-26 2020-10-29 Accelerated Biosciences Corp Induced hepatocytes and uses thereof
AU2016243128A1 (en) * 2015-03-27 2017-11-02 University Of Southern California HLA-G as a novel target for CAR T-cell immunotherapy
EP3328377A4 (en) * 2015-07-31 2019-03-13 Tarveda Therapeutics, Inc. COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGICAL THERAPIES
KR20190019068A (en) 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-cell modulated multimeric polypeptides and methods for their use
CN109689096A (en) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 Variant PD-L1 polypeptides, T cell regulatory multimer polypeptides, and methods of using the same
TW201829463A (en) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 anti-HLA-G antibody and use thereof
PT3558339T (en) 2016-12-22 2024-03-15 Cue Biopharma Inc MULTIMER POLYPEPTIDES THAT MODULATE T CELLS AND METHODS OF USE THEREOF
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3054955A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
AR114789A1 (en) 2018-04-18 2020-10-14 Hoffmann La Roche ANTI-HLA-G ANTIBODIES AND THE USE OF THEM
CN115057932A (en) 2018-09-27 2022-09-16 提泽纳治疗公司 Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies, and methods of using anti-HLA-G antibodies
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2023541366A (en) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド MHC class II T cell modulating multimeric polypeptides and methods of use thereof to treat type 1 diabetes mellitus (T1D)
CR20230263A (en) 2020-12-17 2023-08-21 Hoffmann La Roche Anti-hla-g antibodies and use thereof
US20250011390A1 (en) * 2021-12-02 2025-01-09 Texas Tech University System Single-Chain Immune Modulator (SCIM)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011044A1 (en) * 2005-07-15 2007-01-25 Kyushu University, National University Corporation Pharmaceutical composition comprising disulfide-linked hla-g dimer and process for production of disulfide-linked hla-g dimer
WO2010052228A1 (en) * 2008-11-07 2010-05-14 Hla-G Technologies Hla-g proteins and pharmaceutical uses thereof
WO2010150235A1 (en) * 2009-06-25 2010-12-29 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717498B1 (en) 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcripts of the HLA-G class I MHC gene and their applications.
JP4470007B2 (en) 1998-02-20 2010-06-02 コミサリア・ア・レネルジー・アトミーク Method for selecting tumors that express HLA-G and are sensitive to anti-cancer therapy and uses thereof
FR2794977B1 (en) 1999-06-18 2003-10-31 Commissariat Energie Atomique USE OF COMPOSITIONS CONTAINING SOLUBLE FORMS OF HLA-G IN THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS AND THEIR METHOD OF OBTAINING
FR2810047B1 (en) 2000-06-13 2004-04-02 Commissariat Energie Atomique NEW ISOFORM OF HLA-G AND ITS APPLICATIONS
US20040044182A1 (en) * 2001-09-17 2004-03-04 Hunt Joan S Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g
US20040210037A1 (en) * 2003-03-28 2004-10-21 Vaccinex, Inc. Targeted MHC class I alpha3 vaccine delivery systems
WO2007091078A2 (en) * 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
FR2934498B1 (en) 2008-08-01 2014-08-15 Commissariat Energie Atomique USE OF A SOLUBLE FORM OF HLA-G IN THE TREATMENT OF ABNORMAL PROLIFERATIONS OF B LYMPHOCYTES.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011044A1 (en) * 2005-07-15 2007-01-25 Kyushu University, National University Corporation Pharmaceutical composition comprising disulfide-linked hla-g dimer and process for production of disulfide-linked hla-g dimer
WO2010052228A1 (en) * 2008-11-07 2010-05-14 Hla-G Technologies Hla-g proteins and pharmaceutical uses thereof
WO2010150235A1 (en) * 2009-06-25 2010-12-29 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLEMENTS CRAIG S ET AL: "Structural studies on HLA-G: implications for ligand and receptor binding.", HUMAN IMMUNOLOGY APR 2007 LNKD- PUBMED:17400055, vol. 68, no. 4, April 2007 (2007-04-01), pages 220 - 226, XP002623221, ISSN: 0198-8859 *
LI CHANGLIN ET AL: "HLA-G homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 106, no. 14, April 2009 (2009-04-01), pages 5767 - 5772, XP002623222, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
CA2764860A1 (en) 2010-12-29
CA2764860C (en) 2018-04-24
US9359424B2 (en) 2016-06-07
EP2445935A1 (en) 2012-05-02
JP5736368B2 (en) 2015-06-17
JP2012531400A (en) 2012-12-10
WO2010150233A2 (en) 2010-12-29
EP2445934B1 (en) 2014-07-16
EP2445934A2 (en) 2012-05-02
CA2764649C (en) 2019-02-26
US20120178703A1 (en) 2012-07-12
WO2010150235A1 (en) 2010-12-29
CA2764649A1 (en) 2010-12-29
ES2515241T3 (en) 2014-10-29
ES2546509T3 (en) 2015-09-24
EP2445935B1 (en) 2015-07-01
JP2012531401A (en) 2012-12-10
US20180194830A1 (en) 2018-07-12
US11401318B2 (en) 2022-08-02
US20120164164A1 (en) 2012-06-28
JP5802661B2 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
WO2010150233A3 (en) Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
WO2012158962A3 (en) Improved peptide pharmaceuticals
WO2012012352A3 (en) Modified peptides and proteins
WO2012158965A3 (en) Improved peptide pharmaceuticals for insulin resistance
WO2011036445A3 (en) Polypeptides and uses thereof
NZ602522A (en) Biosynthetic proline/alanine random coil polypeptides and their uses
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
WO2013003045A3 (en) Procoagulant peptides and their derivatives and uses therefor
EP2594581A3 (en) Peptide vaccines with Seq Id No: 178, 174, 186 or 194 for cancers expressing tumor-associated antigens
UA118167C2 (en) Peptides and their use
RU2016146198A (en) THERAPEUTIC DLL4-BINDING PROTEINS
MY162564A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
UA97516C2 (en) Fully human anti-vap-1 monoclonal antibody
WO2009142460A3 (en) Antibody-peptide fused synergibody
WO2012083078A3 (en) Croos-linked peptides and proteins, methods of making same, and uses thereof
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2008093058A3 (en) Peptides and their use
PH12013500143A1 (en) A method of treating alzheimer`s disease
WO2013014677A8 (en) Matrix compositions for controlled release of peptide and polypeptide molecules
EP2481748A3 (en) Foxp3 peptide vaccine
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
WO2009120895A3 (en) Recombinant bacteriophages useful for tissue engineering
WO2013054110A3 (en) Compositions for binding to amyloid proteins
WO2010057275A8 (en) Cyclic peptides and uses thereof
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10732451

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2764860

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012516958

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010732451

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10732451

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13379525

Country of ref document: US